InxMed Co., Ltd.
http://en.inxmed.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From InxMed Co., Ltd.
Deal Watch: Lilly Sends European Commercial Rights For Two Migraine Drugs To Organon
Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.
Asia Deal Watch: Astellas Expands Protein Degrader R&D Capability With PeptiDream Collaboration
Plus deals involving Santen/Harrow/Visiox, Aurobindo/BioFactura, AFT/Crossject, Imugene/RenovoRx, Biotheus/BioNTech, GeneQuantum/InxMed, ObsEva/Yuyuan, Monopar/National University of Singapore and Doer Biologics/BioNTech.
Finance Watch: VC Mega-Rounds Are Alive And Well
Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.
RNA-Based Therapies Back In Spotlight As Chinese Biotechs Raise $366m
Four Chinese RNA technology developers, including Rona Therapeutics and METiS Pharmaceuticals, have bagged the most proceeds in recent financing rounds in the country backed by venture capital and private equity funds.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- InxMed (Shanghai) Co., Ltd.
- iPharma Limited
- iPharma Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice